Helen Collins

Helen is the Chief Medical Officer at Enliven Therapeutics. Prior to joining Enliven, Helen served as Chief Medical Officer and Executive Vice President at Five Prime Therapeutics, a clinical-stage biotechnology company focused on oncology that was acquired by Amgen, Inc. She serves as a member of the board of directors of Kura Oncology.

Previously, Helen held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Program and Clinical Lead for Gilead’s BTK and BET inhibitor programs. Helen also held positions of increasing responsibility at Amgen, most recently as Global Lead, Oncology Biosimilars. Prior to joining Amgen, Helen practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group and served as President for three years.

Helen earned an M.D. from Johns Hopkins University School of Medicine and an A.B. in Chemistry from Bryn Mawr College. She completed her residency in internal medicine at Johns Hopkins Hospital and completed her fellowship at Stanford University School of Medicine, where she concentrated on gastrointestinal cancer. Helen is board certified in oncology.